Clariant AG

Clariant is a specialty chemicals group based in Switzerland. Co. develops, manufactures, distributes and sells a broad range of specialty chemicals which play a key role in its customers' manufacturing and treatment processes or add value to their end products. Co. has manufacturing plants around the world and sells mainly in countries within Europe, the Americas and Asia. Co.'s businesses are organized into four business areas: Care Chemicals (BU Industrial & Consumer Specialties), Catalysis & Energy (BU Catalysts, Business Line Energy Storage), Natural Resources (BU Oil & Mining Services, BU Functional Minerals), and Plastics & Coatings (BU Additives, BU Masterbatches, BU Pigments).
  • TickerCLN
  • ISINCH0012142631
  • ExchangeSix Swiss Exchange
  • SectorChemicals
  • CountrySwitzerland

Analysts

Clariant – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Rob Hales

Morningstar | Clariant's 4Q Worse Than It Looks at First Glance; Shares Fairly Valued

No-moat Clariant reported fourth-quarter EBITDA of CHF 253 million, down 2% from 2017 and below consensus but ahead of our estimate by nearly 10%. The underlying numbers paint a weaker picture. EBITDA was buoyed by a surprise positive performance in catalysis, which saw higher-than-expected petrochemical sales and some orders pulled forward that were scheduled for the first quarter of 2019. This business is notoriously lumpy, and indications from the company last quarter would lead one to believe that the fourth quarter was going to be much weaker. Ignoring the catalysis beat would have result...

Rob Hales

Clariant's 4Q Worse Than It Looks at First Glance; Shares Fairly Valued

No-moat Clariant reported fourth-quarter EBITDA of CHF 253 million, down 2% from 2017 and below consensus but ahead of our estimate by nearly 10%. The underlying numbers paint a weaker picture. EBITDA was buoyed by a surprise positive performance in catalysis, which saw higher-than-expected petrochemical sales and some orders pulled forward that were scheduled for the first quarter of 2019. This business is notoriously lumpy, and indications from the company last quarter would lead one to believ...

MarketLine Department

Huntsman Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Huntsman Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Huntsman Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage...

MarketLine Department

Arkema SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Arkema SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Arkema SA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights Thi...

Clariant AG: Update Following Outlook Change to Positive

A detailed rationale for Clariant’s Ba1 rating following the change in the outlook to positive from stable.

Moody's changes outlook on Clariant's Ba1 ratings to positive from stable

Rating Action: Moody's changes outlook on Clariant's Ba1 ratings to positive from stable. Global Credit Research- 17 Dec 2018. London, 17 December 2018-- Moody's Investors Service, today changed the outlook on all ratings of Clariant AG to positive from stable.

Clariant AG - June 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Clariant AG - December 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Clariant AG: Update Following Outlook Change to Stable

CORPORATES CREDIT OPINION 19 December 2017 Update RATINGS Clariant AG Domicile Muttenz, Switzerland Long Term Rating Ba1 Type LT Corporate Family Ratings - Fgn Curr Outlook Stable Please see the  ratings section  at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Francois Lauras 44-20-7772-5397

Rob Hales

Morningstar | Clariant's 4Q Worse Than It Looks at First Glance; Shares Fairly Valued

No-moat Clariant reported fourth-quarter EBITDA of CHF 253 million, down 2% from 2017 and below consensus but ahead of our estimate by nearly 10%. The underlying numbers paint a weaker picture. EBITDA was buoyed by a surprise positive performance in catalysis, which saw higher-than-expected petrochemical sales and some orders pulled forward that were scheduled for the first quarter of 2019. This business is notoriously lumpy, and indications from the company last quarter would lead one to believe that the fourth quarter was going to be much weaker. Ignoring the catalysis beat would have result...

Rob Hales

Clariant's 4Q Worse Than It Looks at First Glance; Shares Fairly Valued

No-moat Clariant reported fourth-quarter EBITDA of CHF 253 million, down 2% from 2017 and below consensus but ahead of our estimate by nearly 10%. The underlying numbers paint a weaker picture. EBITDA was buoyed by a surprise positive performance in catalysis, which saw higher-than-expected petrochemical sales and some orders pulled forward that were scheduled for the first quarter of 2019. This business is notoriously lumpy, and indications from the company last quarter would lead one to believ...

Rob Hales

Morningstar | CLN Updated Forecasts and Estimates from 24 Jan 2019

No-moat Clariant reported third-quarter results that were broadly in line with our expectations, with EBITDA of CHF 246 million up 3% over the prior-year period. A very strong result in care chemicals more than offset a weaker-than-expected quarter in catalysis. A couple of items in the outlook caught our eye. First, Clariant stated that China softened in the quarter, a sensitive topic for investors in the current market. Second, Clariant confirmed its guidance for 2018 but altered its outlook for the economic environment, noting that mature markets are expected to grow at a slower pace. We do...

Rob Hales

Morningstar | Solid 3Q for Clariant on Record Margins in Care Chemicals; Shares Fairly Valued

No-moat Clariant reported third-quarter results that were broadly in line with our expectations, with EBITDA of CHF 246 million up 3% over the prior-year period. A very strong result in care chemicals more than offset a weaker-than-expected quarter in catalysis. A couple of items in the outlook caught our eye. First, Clariant stated that China softened in the quarter, a sensitive topic for investors in the current market. Second, Clariant confirmed its guidance for 2018 but altered its outlook for the economic environment, noting that mature markets are expected to grow at a slower pace. We do...

Rob Hales

Solid 3Q for Clariant on Record Margins in Care Chemicals; Shares Fairly Valued

No-moat Clariant reported third-quarter results that were broadly in line with our expectations, with EBITDA of CHF 246 million up 3% over the prior-year period. A very strong result in care chemicals more than offset a weaker-than-expected quarter in catalysis. A couple of items in the outlook caught our eye. First, Clariant stated that China softened in the quarter, a sensitive topic for investors in the current market. Second, Clariant confirmed its guidance for 2018 but altered its outlook f...

A director sold 12,821 shares at 25.429CHF and

A director at Clariant Ag sold 12,821 shares at 25.429CHF and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

CLARIANT AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of CLARIANT AG (CH), a company active in the Specialty Chemicals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date January 18, 2019, the closing price was CHF 19.88 and its potential was estimated at CHF 21.63.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Huntsman Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Huntsman Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Huntsman Corporation since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage...

MarketLine Department

Arkema SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Arkema SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Arkema SA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights Thi...

MarketLine Department

Royal DSM N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Royal DSM N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Royal DSM N.V. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highl...

Clariant – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch